cagrilintide with semaglutide Co-formulation of and Shows Promise Against Diabetes and Obesity In a phase 3a study

Phase 2 body composition substudy data using DEXA scans showed that retatrutide participants lost predominantly fat mass, with a favorable fat-to-lean mass loss ratio

Additional microbiological testing confirmed no detectable aerobic microorganisms, yeasts or moulds, supporting laboratory-grade quality standards suitable for controlled scientific investigation

For related laboratory research topics, see Retatrutide Research Overview, Peptide Purity, Storage Best Practices, and Peptide Synthesis

Statistical analysis Baseline characteristics of participants were summarized as mean standard deviation (SD) for continuous variables and percentages for categorical variables